AURORA PROGRAM: Messages for the daily clinic
The benefit of immunotherapy in patients with metastatic breast cancer is primarily observed in those with triple negative breast cancer and PD-L1 expression in the tumor sample. To gain a deeper understanding of the immune response failure in metastatic breast cancer, multi-omics characterization of the anti-cancer immune response is being conducted. This research holds the potential to provide novel insights into the underlying mechanisms.
Dr. Roberto Salgado, from the Department of Pathology at GZA-ZNA Hospitals in Antwerp, Belgium, translates the findings of this research project into practical guidelines for implementation in the daily clinical setting. His expertise will contribute to bridging the gap between research discoveries and their application in clinical practice.
With the educational support of:
